Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 12/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CA12 | O43570 | 5/20 | 0.61 |
| ▸ | RPA1 | P27694 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152904 | 0.87 | MAPT (0.77) | ALPLCA9CA12RPA1MAPT | |
| SCHEMBL28195524 | 0.83 | ALPL (0.71) | ALPLCA9CA12RPA1TP53 | |
| SCHEMBL14152359 | 0.79 | ALPL (1.00) | ALPLCA9CA12RPA1MAPT | |
| SCHEMBL16682102 | 0.79 | NPC1 (0.54) | MAPTMEN1GAAKMT2ALMNA | |
| SCHEMBL22646258 | 0.78 | ALPL (0.62) | ALPLCA9CA12RPA1MAPT | |
| SCHEMBL4097796 | 0.78 | ALPL (0.64) | ALPLCA9CA12RPA1MAPT | |
| SCHEMBL25196067 | 0.77 | ALPL (0.62) | ALPLCA9CA12RPA1MAPT | |
| SCHEMBL2056467 | 0.77 | SMN1; SMN2 (0.57) | MAPTMEN1GAAKMT2ATP53 | |
| SCHEMBL1926175 | 0.77 | MAPT (0.55) | ALPLMAPTMEN1GAAKMT2A | |
| SCHEMBL3447352 | 0.76 | ALPL (1.00) | ALPLCA9CA12RPA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | disclosed |
| US-20040019039-A1 | Substituted piperazines and diazepanes | HIGH POINT PHARMACEUTICALS, LLC | 2004-01-29 | — | — | US | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | ALPL 4069/4885CA9 4838/4885CA12 3539/4885 |
| US-20040019039-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | ALPL 4069/4885CA9 4838/4885CA12 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.